Literature DB >> 20548340

Relationship between TNFA, TNFB and TNFRII gene polymorphisms and outcome after unrelated hematopoietic cell transplantation in a Chinese population.

H W Xiao1, X Y Lai, Y Luo, J M Shi, Y M Tan, J S He, W Z Xie, L Li, X L Zhu, J J Zhu, J Sun, G Q Wei, L Jin, L Z Liu, K N Wu, X H Yu, Z Cai, M F Lin, X J Ye, H Huang.   

Abstract

This study aimed to analyze the association between cytokine gene polymorphisms and outcome following allogeneic hematopoietic SCT (allo-HSCT). A total of 138 unrelated donor/recipient pairs who underwent allo-HSCT from 2001 to 2009 were tested for TNFA-1031 (T>C), -863 (C>A), -857 (C>T), -238 (G>A), TNFB+252 (A>G) and TNFRII codon 196 (T>G) single nucleotide polymorphisms by multiplex SnaPshot analysis. Transplantation involving recipients and/or donors with TNFA-857 C/C genotype or TNFB+252 G allele-positivity resulted in a higher incidence of acute GVHD (aGVHD), which was independent of HLA mismatching. In multivariate analysis, TNFA-857 C/C genotype donors (relative risk (RR)=2.29, P=0.006) and TNFB+252 G allele-positive recipients (RR=1.789, P=0.036) were found to be significantly associated with an increased incidence of aGVHD. TNFA-857 C/C genotype donors (RR=3.748, P=0.002) and TNFB+252 G allele-positive recipients (RR=1.823, P=0.063) were also associated with the development of grades II-IV aGVHD. TNFRII polymorphism in recipients was also related to relapse rate, but no significant associations were found between TNFA, TNFB or TNFRII 196 genotype and cGVHD, relapse or overall survival after transplantation. These results provide the first report of an association between TNFA, TNFB and TNFRII polymorphic features and outcome of allo-HSCT in a Chinese population, and suggest an interaction between TNFA-857 and TNFB+252 genotypes and risk of aGVHD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20548340     DOI: 10.1038/bmt.2010.135

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  9 in total

1.  Combining therapeutic antibodies using basiliximab and etanercept for severe steroid-refractory acute graft-versus-host disease: A multi-center prospective study.

Authors:  Yamin Tan; Haowen Xiao; Depei Wu; Yi Luo; Jianping Lan; Qifa Liu; Kang Yu; Jimin Shi; Jingsong He; Weiyan Zheng; Xiaoyu Lai; Yuanyuan Zhu; Kaili Du; Yishan Ye; Yanmin Zhao; Gaofeng Zheng; Yongxian Hu; Xiaoyan Han; Yanlong Zheng; Guoqing Wei; Zhen Cai; He Huang
Journal:  Oncoimmunology       Date:  2017-01-06       Impact factor: 8.110

2.  SOD2 rs4880 CT/CC genotype predicts poor survival for Chinese gastric cancer patients received platinum and fluorouracil based adjuvant chemotherapy.

Authors:  Zhi Xu; Yi Chen; Dongying Gu; Nikki P Lee; Stella Sun; Weida Gong; Yongfei Tan; John M Luk; Jinfei Chen
Journal:  Am J Transl Res       Date:  2015-02-15       Impact factor: 4.060

3.  Donor TLR9 gene tagSNPs influence susceptibility to aGVHD and CMV reactivation in the allo-HSCT setting without polymorphisms in the TLR4 and NOD2 genes.

Authors:  H W Xiao; Y Luo; X Y Lai; J M Shi; Y M Tan; J S He; W Z Xie; W Y Zheng; X J Ye; X H Yu; Z Cai; M F Lin; H Huang
Journal:  Bone Marrow Transplant       Date:  2013-10-14       Impact factor: 5.483

4.  Genetic variations in T-cell activation and effector pathways modulate alloimmune responses after allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies.

Authors:  Haowen Xiao; Yi Luo; Xiaoyu Lai; Shan Fu; Jimin Shi; Yamin Tan; Jingsong He; Wanzhuo Xie; Weiyan Zheng; Li-Mengmeng Wang; Lifei Zhang; Lizhen Liu; Xiujin Ye; Xiaohong Yu; Zhen Cai; Maofang Lin; He Huang
Journal:  Haematologica       Date:  2012-06-24       Impact factor: 9.941

5.  Replication and validation of genetic polymorphisms associated with survival after allogeneic blood or marrow transplant.

Authors:  Ezgi Karaesmen; Abbas A Rizvi; Leah M Preus; Philip L McCarthy; Marcelo C Pasquini; Kenan Onel; Xiaochun Zhu; Stephen Spellman; Christopher A Haiman; Daniel O Stram; Loreall Pooler; Xin Sheng; Qianqian Zhu; Li Yan; Qian Liu; Qiang Hu; Amy Webb; Guy Brock; Alyssa I Clay-Gilmour; Sebastiano Battaglia; David Tritchler; Song Liu; Theresa Hahn; Lara E Sucheston-Campbell
Journal:  Blood       Date:  2017-08-15       Impact factor: 22.113

6.  Polymorphism in one-carbon metabolism pathway affects survival of gastric cancer patients: Large and comprehensive study.

Authors:  Tingting Zhao; Dongying Gu; Zhi Xu; Xinying Huo; Lili Shen; Chun Wang; Yongfei Tang; Peng Wu; Jason He; Weida Gong; Ming-Liang He; Jinfei Chen
Journal:  Oncotarget       Date:  2015-04-20

7.  Genomic variants in Fas-mediated apoptosis pathway predict a poor response to Platinum-based Chemotherapy for Chinese Gastric Cancer Patients.

Authors:  Tingting Zhao; Wei Li; Jinfei Chen; Weisong Qin
Journal:  J Cancer       Date:  2021-01-01       Impact factor: 4.207

8.  A genetic polymorphism in TOX3 is associated with survival of gastric cancer in a Chinese population.

Authors:  Xiaojing Zhang; Haixia Zhu; Xiaomin Wu; Meilin Wang; Dongying Gu; Weida Gong; Zhi Xu; Yongfei Tan; Yongling Gong; Jianwei Zhou; Cuiju Tang; Na Tong; Jinfei Chen; Zhengdong Zhang
Journal:  PLoS One       Date:  2013-09-17       Impact factor: 3.240

9.  The effects of genomic polymorphisms in one-carbon metabolism pathways on survival of gastric cancer patients received fluorouracil-based adjuvant therapy.

Authors:  Tingting Zhao; Zhi Xu; Dongying Gu; Peng Wu; Xinying Huo; Xiaowei Wei; Yongfei Tang; Weida Gong; Ming-Liang He; Jinfei Chen
Journal:  Sci Rep       Date:  2016-07-26       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.